177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Open accessAbstract
Background [177 Lu]Lu-PSMA-617 (177 Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of 177 Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer.Methods In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous 177 Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling). Crossover from ARPI change to 177 Lu-PSMA-617 was allowed after centrally confirmed radiographic progression. The primary endpoint was radiographic progression-free survival, defined as the time from randomisation until radiographic progression or death, assessed in the intention-to-treat population. Safety was a secondary endpoint. This study is registered with ClinicalTrials.gov (NCT04689828) and is ongoing. In this primary report of the study, we present primary (first data cutoff) and updated (third data cutoff) analyses of radiographic progression-free survival; all other data are based on the third data cutoff.Findings Overall, of the 585 patients screened, 468 met all eligibility criteria and were randomly allocated between June 15, 2021 and Oct 7, 2022 to receive 177 Lu-PSMA-617 (234 [50%] patients) or ARPI change (234 [50%]). Baseline characteristics were mostly similar between groups; median number of 177 Lu-PSMA-617 cycles was 6·0 (IQR 4·0-6·0). Of patients assigned to ARPI change, 134 (57%) crossed over to receive 177 Lu-PSMA-617. In the primary analysis (median time from randomisation to first data cutoff 7·26 months [IQR 3·38-10·55]), the median radiographic progression-free survival was 9·30 months (95% CI 6·77-not estimable) in the 177 Lu-PSMA-617 group versus 5·55 months (4·04-5·95) in the ARPI change group (hazard ratio [HR] 0·41 [95% CI 0·29-0·56]; p<0·0001). In the updated analysis at time of the third data cutoff (median time from randomisation to third data cutoff 24·11 months [IQR 20·24-27·40]), median radiographic progression-free survival was 11·60 months (95% CI 9·30-14·19) in the 177 Lu-PSMA-617 group versus 5·59 months (4·21-5·95) in the ARPI change group (HR 0·49 [95% CI 0·39-0·61]). The incidence of grade 3-5 adverse events was lower in the 177 Lu-PSMA-617 group (at least one event in 81 [36%] of 227 patients; four [2%] grade 5 [none treatment related]) than the ARPI change group (112 [48%] of 232; five [2%] grade 5 [one treatment related]).Interpretation 177 Lu-PSMA-617 prolonged radiographic progression-free survival relative to ARPI change, with a favourable safety profile. For patients with PSMA-positive metastatic castration-resistant prostate cancer who are being considered for a change of ARPI after progression on a previous ARPI, 177 Lu-PSMA-617 may be an effective treatment alternative.Funding Novartis.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In taxane-naive mCRPC patients who had disease progression on an ARPI, 177Lu-PSMA-617 as earlier-line therapy before chemotherapy improved rPFS compared with changing to an alternate ARPI (median 11.6 vs 5.59 months; HR 0.49).
“The findings in the third data cutoff point thus far showed that those in the experimental group exhibited a statistically significant improvement in rPFS compared to the ARPI change group (median 11.6 months vs 5.59 months; HR:0.49).”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [14]
In PSMAfore, 177Lu-PSMA-617 was generally well-tolerated with lower incidence of grade 3-5 adverse events compared with control, while OS data were not fully mature.
“Preliminary safety analysis indicated that 177Lu-PSMA- 617 was generally well-tolerated with lower incidence of grade 3–5 adverse events as compared to control group, while OS data is still not fully mature”
From PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · see citing works
Self-citationIntegrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645 · see citing works
Self-citationLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., Vaishampayan, N., El-Haddad, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107322 · Cited by 2,864 · see citing works
Self-citationOlaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323 · see citing works
Self-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680 · see citing works
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,665 · see citing works
Self-citation(1997) · PubMed · Cited by 1,541 · see citing works
Hofman, M. S., Violet, J. A., Hicks, R. J., Ferdinandus, J., Thang, S. P., Akhurst, T. J., Iravani, A., Kong, G., Kumar, A. S. R., Murphy, D. G., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30198-0 · Cited by 1,184 · see citing works
Hofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., Ng, S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00237-3 · Cited by 1,170 · see citing works
Defining the clinically important difference in pain outcome measures
Farrar, J. T., Portenoy, R. K., Berlin, J. A., Kinman, J. L., & Strom, B. L. (2000) · Pain · doi:10.1016/s0304-3959(00)00339-0 · Cited by 1,071 · see citing works
Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Parker, C., Castro, E., Fizazi, K., Heidenreich, A., Ost, P., Procopio, G., Tombal, B., & Gillessen, S. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.06.011 · Cited by 977 · see citing works
Self-citationRahbar, K., Ahmadzadehfar, H., Kratochwil, C., Haberkorn, U., Schäfers, M. A., Essler, M., Baum, R. P., Kulkarni, H., Schmidt, M. C., Drzezga, A. E., et al. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.183194 · Cited by 849 · see citing works
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792 · see citing works
Self-citationEsper, P., Mo, F., Chodak, G., Sinner, M., Cella, D., & Pienta, K. J. (1997) · Urology · doi:10.1016/s0090-4295(97)00459-7 · Cited by 696 · see citing works
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546 · see citing works
Self-citationProstate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer
Paschalis, A., Sheehan, B., Riisnaes, R., Rodrigues, D. N., Gurel, B., Bertan, C., Ferreira, A., Lambros, M. B. K., Seed, G., Yuan, W., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.06.030 · Cited by 455 · see citing works
Rucaparib or Physician’s Choice in Metastatic Prostate Cancer
Fizazi, K., Piulats, J. M., Reaume, M. N., Ostler, P., McDermott, R., Gingerich, J. R., Pintus, E., Sridhar, S. S., Bambury, R. M., Emmenegger, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214676 · Cited by 449 · see citing works
Self-citationKhalaf, D. J., Annala, M., Taavitsainen, S., Finch, D. L., Oja, C. D., Vergidis, J., Zulfiqar, M., Sunderland, K., Azad, A., Kollmannsberger, C., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30688-6 · Cited by 362 · see citing works
Self-citationPowles, T. B., Yuen, K. C. Y., Gillessen, S., Kadel, E. E., Rathkopf, D. E., Matsubara, N., Drake, C. G., Fizazi, K. S., Piulats, J. M., Wysocki, P. J., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01600-6 · Cited by 262 · see citing works
Self-citationHofman, M. S., Emmett, L., Sandhu, S., Iravani, A., Buteau, J. P., Joshua, A. M., Goh, J. C., Pattison, D. A., Tan, T. H., Kirkwood, I. D., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00529-6 · Cited by 230 · see citing works
Cella, D. F., Nichol, M. B., Eton, D. T., Nelson, J. B., & Mulani, P. M. (2008) · Value in Health · doi:10.1111/j.1524-4733.2008.00409.x · Cited by 213 · see citing works
Emmett, L., Subramaniam, S., Crumbaker, M., Nguyen, A., Joshua, A. M., Weickhardt, A., Lee, S.-T., Ng, S., Francis, R. J., Goh, J. C., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00135-9 · Cited by 195 · see citing works
George, D. J., Sartor, O. A., Miller, K., Fred Saad, C., TOMBAL, B. F., Kalinovský, J., Jiao, X., Tangirala, K., Sternberg, C. N., & Higano, C. S. (2020) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2019.12.019 · Cited by 179 · see citing works
Self-citationAttard, G., Borre, M., Gurney, H., Loriot, Y., Andresen-Daniil, C., Kalleda, R., Pham, T. M., Taplin, M., & collaborators, O. B. O. T. P. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.77.9827 · Cited by 173 · see citing works
Gillessen, S., Bossi, A., Davis, I. D., Bono, J. S. D., Fizazi, K. S., James, N. D., Mottet, N., Shore, N. D., Small, E. J., Smith, M. R., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.018 · Cited by 171 · see citing works
Self-citationApalutamide and overall survival in non-metastatic castration-resistant prostate cancer
Small, E. J., Fred Saad, C., Chowdhury, S., Oudard, S. M., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., Lee, J. Y., Uemura, H., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz397 · Cited by 144 · see citing works
Recent Advances in the Management of Metastatic Prostate Cancer
Sayegh, N., Swami, U., & Agarwal, N. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00206 · Cited by 143 · see citing works
Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00158-4 · Cited by 125 · see citing works
Self-citationFreedland, S. J., Davis, M. M., Epstein, A. J., Arondekar, B. V., & Ivanova, J. I. (2023) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-023-00725-8 · Cited by 124 · see citing works
Brief Pain Inventory Short Form
Cleeland, C. S. (1991) · PsycTESTS Dataset · doi:10.1037/t04175-000 · Cited by 124 · see citing works
Bono, J. S. D., Chowdhury, S., Feyerabend, S., Elliott, T., Grande, E., Melhem‐Bertrandt, A., Baron, B., Hirmand, M., Werbrouck, P., & Fizazi, K. S. (2017) · European Urology · doi:10.1016/j.eururo.2017.07.035 · Cited by 119 · see citing works
Self-citationStatus of PSMA-targeted radioligand therapy in prostate cancer: current data and future trials
Jang, A., Kendi, A. T., & Sartor, O. A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231157632 · Cited by 101 · see citing works
Self-citationShore, N. D., Laliberté, F., Ionescu‐Ittu, R., Yang, L., Mahendran, M., Lejeune, D., Yu, L., Burgents, J. E., Duh, M. S., & Ghate, S. R. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01823-6 · Cited by 98 · see citing works
Self-citationPSMA-Targeted Radiopharmaceuticals in Prostate Cancer: Current Data and New Trials
Ramnaraign, B. H., & Sartor, O. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyac279 · Cited by 73 · see citing works
Self-citationSartor, O., Castellano Gauna, D. E., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N. N., Crosby, M., Piulats Rodriguez, J. M., Flechon, A., Wei, X. X., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.085 · Cited by 71 · see citing works
Self-citationAl-Batran, S.-E., Hozaeel, W., Tauchert, F. K., Hofheinz, R., Hinke, A., Windemuth-Kieselbach, C., Hübner, A., Burmester, M., Koenigsmann, M., Wiegand, J., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv129 · Cited by 66 · see citing works
Population-based study on use of chemotherapy in men with castration resistant prostate cancer
Lissbrant, I. F., Garmo, H., Widmark, A., & Stattin, P. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.770164 · Cited by 51 · see citing works
Leith, A., Kim, J., Ribbands, A., Clayton, E., Yang, L., & Ghate, S. R. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02073-w · Cited by 35 · see citing works
Agarwal, N., Azad, A., Carles, J., Matsubara, N., Oudard, S. M., Fred Saad, C., Merseburger, A. S., Soares, A., McGregor, B. A., Żurawski, B. A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.2024.42.4_suppl.18 · Cited by 33 · see citing works
Komura, K., Fujiwara, Y., Uchimoto, T., Saito, K., Tanda, N., Matsunaga, T., Ichihashi, A., Tsutsumi, T., Tsujino, T., Yoshikawa, Y., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081251 · Cited by 22 · see citing works
Kuo, P. H., Yoo, D. C., Avery, R., Seltzer, M., Calais, J., Nagarajah, J., Weber, W. A., Fendler, W. P., Hofman, M. S., Krause, B. J., et al. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.265077 · Cited by 22 · see citing works
Self-citationIntravenous therapies for castration-resistant prostate cancer: Toxicities and adverse events
Singer, E. A., & Srinivasan, R. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2011.09.003 · Cited by 21 · see citing works
Crumbaker, M., Emmett, L., Horvath, L. G., & Joshua, A. M. (2019) · JCO Precision Oncology · doi:10.1200/po.18.00237 · Cited by 20 · see citing works
Shayegan, B., Wallis, C. J. D., Malone, S. C., Cagiannos, I., Hamilton, R. J., Ferrario, C., Gotto, G. T., Basappa, N. S., Morgan, S. C., Fernandes, R., et al. (2022) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2022.01.009 · Cited by 18 · see citing works
Zielinski, R., Azad, A., Chi, K. N., & Tyldesley, S. K. (2014) · Canadian Urological Association Journal · doi:10.5489/cuaj.2076 · Cited by 6 · see citing works
Self-citationBroyelle, A., Delanoy, N., Bimbai, A.-M., Deley, M. L., Penel, N., Villers, A. A., Lebellec, L., & Oudard, S. M. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.02.006 · Cited by 6 · see citing works
Ghantoji, S. S., Yu, C., Sawhney, A. G., Byrne, C., Tang, J., Runeckles, K., & Patel, J. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.e17024 · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [52]52. Raychaudhuri R, Mo G, Tuchayi AM, et al. Genomic correlates of prostate-specific membrane antigen expression and response to ¹⁷⁷Lu-PSMA-617: a retrospective multicenter cohort study. JCO Precis Oncol 2024; 8: e2300634.
Cited by
Sorted by citations
Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Sandhu, S. K., Nguyen, A. D. K., Weickhardt, A. J., Lee, S.-T., Ng, S. S. W., Francis, R. J., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00009-9 · Cited by 79 · see citing works
Garje, R., Riaz, I. B., Naqvi, S. A. A., Rumble, R. B., Taplin, M., Kungel, T. M., Herchenhorn, D., Zhang, T., Beckermann, K. E., Vapiwala, N., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00007 · Cited by 69 · see citing works
Buteau, J. P., Kostos, L. K., Jackson, P. A., Xie, J., Haskali, M. B., Alipour, R., McIntosh, L., Emmerson, B., MacFarlane, L., Martin, C. A., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00332-8 · Cited by 66 · see citing works
The molecular blueprint of targeted radionuclide therapy
Primac, I., Tabury, K., Tasdogan, A., Baatout, S., & Herrmann, K. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01069-z · Cited by 59 · see citing works
Self-citationFizazi, K. S., Chi, K. N., Shore, N. D., Herrmann, K., Bono, J. S. D., Castellano, D., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., et al. (2025) · Annals of Oncology · doi:10.1016/j.annonc.2025.07.003 · Cited by 58 · see citing works
Self-citationArmstrong, A. J., Morris, M. J., Abida, W. M., Aggarwal, R. R., Antonarakis, E. S., Attard, G., Beltran, H., Bryce, A. H., Carducci, M. A., Cheng, H. H., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02834 · Cited by 57 · see citing works
Self-citationKwan, E. M., Ng, S. W. S., Tolmeijer, S. H., Emmett, L., Sandhu, S. K., Buteau, J. P., Iravani, A., Joshua, A. M., Francis, R. J., Subhash, V. V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03704-9 · Cited by 47 · see citing works
The contemporary management of prostate cancer
Chakrabarti, D., Albertsen, P. C., Adkins, A., Kishan, A. U., Murthy, V., Parker, C. C., Pathmanathan, A. U., Reid, A. H. M., Sartor, O., van As, N. J., et al. (2025) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.70020 · Cited by 49 · see citing works
Self-citationRecent advances in theranostics and oncology PET: emerging radionuclides and targets
Watabe, T., Hirata, K., Iima, M., Yanagawa, M., Saida, T., Sakata, A., Ide, S., Honda, M., Kurokawa, R., Nishioka, K., et al. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02090-z · Cited by 38 · see citing works
Kishan, A. U., Valle, L., Wilhalme, H., Felix, C., Nabong, R., Juarez-Casillas, J. E., Flores, K., Ma, T. M., Ludwig, V. B., Nakayama, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-01553 · Cited by 37 · see citing works
Targeting the tumour cell surface in advanced prostate cancer
Boixareu, C., Taha, T., Venkadakrishnan, V. B., Bono, J. S. D., & Beltran, H. (2025) · Nature Reviews Urology · doi:10.1038/s41585-025-01014-w · Cited by 38 · see citing works
Ninatti, G., Scilipoti, P., Pini, C., Barletta, F. M., Longoni, M., Gelardi, F., Sollini, M., Gandaglia, G., Sathekge, M. M., Montorsi, F., et al. (2025) · Theranostics · doi:10.7150/thno.106574 · Cited by 32 · see citing works
Fizazi, K. S., Attard, G., Azad, A. A., Baciarello, G., Beltran, H., Bjartell, A., Blanchard, P., Bossaert, F., Castro, E., Comperat, E., et al. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.015 · Cited by 35 · see citing works
Self-citationAgarwal, N., Azad, A., Carles, J., Matsubara, N., Oudard, S. M., Fred Saad, C., Merseburger, A. S., Soares, A., McGregor, B. A., Żurawski, B. A., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00209-8 · Cited by 31 · see citing works
Radioligand Therapy in Cancer Management: A Global Perspective
Ninatti, G., Lee, S. T., & Scott, A. M. (2025) · Cancers · doi:10.3390/cancers17213412 · Cited by 29 · see citing works
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care
Cimadamore, A., Boixareu, C., Sharp, A., Beltran, H., & Bono, J. S. D. (2025) · European Urology · doi:10.1016/j.eururo.2025.06.013 · Cited by 25 · see citing works
Fizazi, K. S., Morris, M. J., Shore, N. D., Chi, K. N., Crosby, M. J., Bono, J. S. D., Herrmann, K., Roubaud, G., Nagarajah, J., Fleming, M. T., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00189-5 · Cited by 22 · see citing works
Self-citationNovel hormone therapies for advanced prostate cancer: Understanding and countering drug resistance
Wang, Z., Wang, J., Li, D., Wu, R., Huang, J., Ye, L., Tuo, Z., Yu, Q., Shao, F., Wusiman, D., et al. (2025) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2025.101232 · Cited by 19 · see citing works
Zhang, D., He, T., Shi, T., Huang, K., & Peng, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1553853 · Cited by 22 · see citing works
Aggarwal, R. R., Vuky, J., VanderWeele, D. J., Rettig, M. B., Heath, E. I., Quigley, D. A., Huang, J., Chumber, A. K., Cheung, A., Foye, A., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01989 · Cited by 19 · see citing works
Advances in Targeted Therapy for Metastatic Prostate Cancer
Grewal, K., Dorff, T. B., Mukhida, S. S., Agarwal, N., & Hahn, A. W. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01323-7 · Cited by 18 · see citing works
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer
Lin, C., Hadfield, M. J., Santopietro, A., Lagos, G., Cheng, L., El-Deiry, W. S., Aggarwal, R., Mega, A., Hyams, E., & Carneiro, B. A. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-01131-0 · Cited by 20 · see citing works
PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future
Ayzman, A., Pachynski, R. K., & Reimers, M. A. (2025) · Current Treatment Options in Oncology · doi:10.1007/s11864-025-01317-5 · Cited by 18 · see citing works
The role of PSMA-based radioligand therapy in hormone-sensitive prostate cancer
Laudicella, R., Bauckneht, M., Burger, I. A., Cacciola, A., Fanti, S., Farolfi, A., Ficarra, V., Iagaru, A. H., Liberini, V., Pergolizzi, S., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07083-8 · Cited by 15 · see citing works
Liu, H., Guo, R., Zhang, X., Hu, J., Sun, S., Sun, S., Liu, J., Yang, Z., & Wang, R. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07617-0 · Cited by 14 · see citing works
Effects of Targeted Radionuclide Therapy on Cancer Cells Beyond the Ablative Radiation Dose
Ferro‐Flores, G., Azorin‐Vega, E. P., Ocampo‐García, B., Luna‐Gutiérrez, M., Cruz-Nova, P., & Meléndez‐Alafort, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146968 · Cited by 13 · see citing works
Prostate Cancer Radioligand Therapy: PSMA and Beyond, Current Landscape and Future Directions
Bent, E. H., & Morris, M. J. (2025) · Current Oncology Reports · doi:10.1007/s11912-025-01686-y · Cited by 14 · see citing works
Self-citationTagawa, S. T., Sartor, O., Piulats, J. M., Fred Saad, C., Fizazi, K. S., Reid, A., Beltran, H., Kramer, G., Mahammedi, H., Eiber, M., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)01092-5 · Cited by 13 · see citing works
Self-citationLee, J.-H., & Kim, T. J. (2025) · Biomedicines · doi:10.3390/biomedicines13051132 · Cited by 13 · see citing works
Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy
Bidkar, A. P., Peter, R., Wadhwa, A., Bobba, K. N., Bidlingmaier, S. M., Meher, N., Chou, J., Greenland, N., Dasari, C., Naik, S., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2850 · Cited by 12 · see citing works
Poon, D. M. C., Cheung, W. S. K., Chiu, P. K., Chung, D. H. S., Kung, J. B. T., Lam, D. C. M., Leung, A. K., Ng, A. C. F., O’Sullivan, J. M., Teoh, J. Y., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1530580 · Cited by 11 · see citing works
Abida, W. M., Beltran, H., & Raychaudhuri, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473636 · Cited by 12 · see citing works
Wei, Z., Zhen, W., Chen, X. S., & Zhang, J. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114543 · Cited by 11 · see citing works
Sandhu, S., Joshua, A. M., Emmett, L., Bressel, M., Anton, A., Spain, L., Horvath, L. G., Pasam, A., Tolmeijer, S. H., Akhurst, T., et al. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00017-3 · Cited by 11 · see citing works
Advanced Imaging for Localized Prostate Cancer
Albers, P., & Kinnaird, A. S. (2024) · Cancers · doi:10.3390/cancers16203490 · Cited by 11 · see citing works
Konopnicki, A., Zaliznyak, M., Roy, M., & Jana, B. (2024) · Discover Oncology · doi:10.1007/s12672-024-01680-z · Cited by 11 · see citing works
The future of androgen receptor targeting in prostate cancer: third-generation inhibitors and beyond
Bernard‐Tessier, A., Naoun, N., Barraud, S., Flippot, R., Pobel, C., Rey, M., Baldini, C., Massard, C., Patrikidou, A., Fuerea, A. C., et al. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251379416 · Cited by 10 · see citing works
Self-citationTaplin, M., Riaz, I. B., Rumble, R. B., Naqvi, S. A. A., Hope, T. A., Dias, M. S. F., He, H., Hotte, S. J., Emamekhoo, H., Murad, M. H., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02693 · Cited by 10 · see citing works
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Turco, F., Gillessen, S., Herrmann, K., Paone, G., & Omlin, A. G. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.267730 · Cited by 11 · see citing works
Self-citationOmics-Mediated Treatment for Advanced Prostate Cancer: Moving Towards Precision Oncology
Fatima, Y., Jobre, K. N., Gómez‐Gómez, E., Małkiewicz, B., Vlahou, A., Mokou, M., Mischak, H., Frantzi, M., & Jankowski, V. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157475 · Cited by 11 · see citing works
Liu, K., Robinson, N., Tekoglu, E., Lozada, J., Yu, I. P. L., Tai, R. A., Özturan, D., Dikbas, U. M., Lack, N. A., Cox, M., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c13307 · Cited by 10 · see citing works
Combining PSMA-Targeted Radiopharmaceutical Therapy with Immunotherapy
Altunay, B., Schäfer, L., Morgenroth, A., Peña, Q., Lammers, T., Saar, M., Mottaghy, F. M., & Lütje, S. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270317 · Cited by 9 · see citing works
Yanagisawa, T., Matsukawa, A., Rajwa, P., Miszczyk, M., Fazekas, T., Pradère, B., Miyajima, K., Enei, Y., Cormio, A., Dematteis, A., et al. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-025-01034-y · Cited by 9 · see citing works
Tendler, S., Gregorio, R. D., Balderes, P. J., Michel, A. L., Hoang, T., Bauer, D., Tully, K. M., Korsen, J. A., Lorenz, I. C., Khan, A. G., et al. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2505785123 · Cited by 9 · see citing works
Self-citationTargeting genomic instability in cancer
Yap, T. A., Manning, H. C., Sapra, P., Mills, G. B., & O’Connor, M. J. (2026) · Cell · doi:10.1016/j.cell.2026.03.035 · Cited by 11 · see citing works
Flauto, F., Neola, G., Caso, C., Signori, A., Fornarini, G., Scagliarini, S., Rossetti, S., Crocetto, F., Grillone, F., Costanzo, F. D., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.06.008 · Cited by 8 · see citing works
PSMA-Directed Theranostics in Prostate Cancer
Jajja, S. A., Sodhi, N., Parent, E. E., & Singh, P. (2025) · Biomedicines · doi:10.3390/biomedicines13081837 · Cited by 9 · see citing works
Belabaci, Z., Sleiay, M., Abdelshafi, A., Otmani, Z., Moubarak, E. S., & Amer, F. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102398 · Cited by 8 · see citing works
ESUR: Opportunities for PSMA-PET/CT and whole-body MRI in advanced prostate cancer
Woo, S., Russo, L., Withey, S. J., Dehghanpour, A., García‐Figueiras, R., Schoots, I. G., Petralia, G., Lakhani, A., Penzkofer, T., Pecoraro, M., et al. (2025) · European Radiology · doi:10.1007/s00330-025-12089-9 · Cited by 8 · see citing works
Saeed, F., Berchuck, J. E., Bilen, M. A., Gandhi, J. S., Nazha, B., Brown, J. T., Schuster, D. M., Jani, A. B., Yu, J., & Harik, L. R. (2025) · Cancer · doi:10.1002/cncr.70037 · Cited by 8 · see citing works
Civelek, A. C. (2026) · Cancers · doi:10.3390/cancers18020234 · Cited by 7 · see citing works
Clonal Hematopoiesis after 177Lu-PSMA-617 Radioligand Therapy in Prostate Cancer
Munzur, A. D., Herberts, C., Kwan, E. M., Emmett, L., Sandhu, S., Buteau, J. P., Iravani, A., Joshua, A. M., Francis, R. J., Lee, S.-T., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4001 · Cited by 7 · see citing works
PSMA PET as a Tool for Active Surveillance of Prostate Cancer—Where Are We at?
Carll, J., Bonaddio, J., & Lawrentschuk, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103580 · Cited by 7 · see citing works
Koh, N., Wei, M.-C., Lam, W., Tong, A., Kanesvaran, R., Wong, A., Chen, K., & Thang, S. (2025) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.14174 · Cited by 5 · see citing works
Satapathy, S., Das, C. K., Goyal, S., Sood, A. K., Periasamy, K., Aggarwal, P., Preet, K., Singh, S., Mavuduru, R. S., Bora, G. S., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.269913 · Cited by 6 · see citing works
Kudura, K., Schaulin, Y., Templeton, A. J., Zellweger, T., Harms, W., Georis, R., Kreissl, M. C., & Foerster, R. (2025) · Cancers · doi:10.3390/cancers17132249 · Cited by 6 · see citing works
[177Lu]Lu-PSMA SPECT/CT for early response assessment using quantitative RECIP 1.0
Kassas, M., Devriendt, L., Manley, M., Guiot, T., Marin, C., Danieli, R., Taraji, L., Kristanto, P., Karfis, I., Woff, E., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07613-4 · Cited by 6 · see citing works
Belabaci, Z., Brignoli, G., Zilli, T., Grujić, M., Mohamad, I., Al‐Ibraheem, A., Shelan, M., & Afshar‐Oromieh, A. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07627-y · Cited by 6 · see citing works
Göğebakan, K. Ç., Kunst, N., Ghodsi, A., Owens, L., Iravani, A., & Etzioni, R. D. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271825 · Cited by 6 · see citing works
Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
Pepin, A. N., Kiess, A. P., Lukens, J. N., Mulugeta, P. G., & Taunk, N. K. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2024.10.014 · Cited by 7 · see citing works
Peng, C., Chen, C.-T., & Tang, I.-C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26135970 · Cited by 7 · see citing works
Nagarajah, J., Kim, H., Nordquist, L. T., Prasad, V., Scott, N., Stevens, D. J., Fongenie, B., & Osborne, J. R. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07313-z · Cited by 5 · see citing works
Self-citationDuong, T. T., Sarno, D. D., Fakir, H., Bauman, G. S., Martinov, M., Thomson, R. M., & Lee, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1600821 · Cited by 5 · see citing works
Bridging the Gap: PSMA Radioligand Therapy for Asian Men with Prostate Cancer
Suh, M., & Joo Hyun, O. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00946-w · Cited by 5 · see citing works
Murthy, V., Kimura, K., Theus, L., Nguyen, A., Grogan, T., Lokre, O., Perk, T., Rettig, M. B., Drakaki, A., Shen, J., et al. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.270916 · Cited by 5 · see citing works
Nikitas, J. N., Holzgreve, A., Juarez, J. E., Kimura, K., Lira, S., Alam, H., Contreras, M., Theus, L., Nguyen, A. T., Ells, Z., et al. (2026) · Journal of Nuclear Medicine · doi:10.2967/jnumed.125.271231 · Cited by 5 · see citing works
Ghodsi, A., Owens, L., Demirci, R. A., Gafita, A., Cheng, H. H., Hawley, J. E., Raychaudhuri, R., Khan, H. M., Sunkara, R., Hsieh, A. C., et al. (2026) · Radiology · doi:10.1148/radiol.250649 · Cited by 5 · see citing works
Wenzel, M., Hoeh, B., Siech, C., Koll, F. J., Humke, C., Groener, D., Steuber, T. P., Graefen, M., Maurer, T., Banek, S., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07076-7 · Cited by 5 · see citing works
Kalender, E., Ekinci, E., Elboğa, U., & Şahin, E. (2025) · Biomedicines · doi:10.3390/biomedicines13030569 · Cited by 5 · see citing works
Ventura, D., Noto, B., Jauregui, N. R., Roll, W., & Rahbar, K. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001300 · Cited by 5 · see citing works
Enei, Y., Yanagisawa, T., Okada, A., Kuruma, H., Okazaki, C., Watanabe, K., Lenzo, N. P., Kimura, T., & Miki, K. (2025) · Annals of Nuclear Medicine · doi:10.1007/s12149-025-02086-9 · Cited by 5 · see citing works
Beyond PSMA: theranostic cell surface targets in metastatic prostate cancer
Ashraf, B., McKenzie, J., & Armstrong, A. J. (2025) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-025-01037-9 · Cited by 5 · see citing works
Baberwal, P., & Basu, S. K. (2025) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2025.2589524 · Cited by 4 · see citing works
Current and future perspectives on radioligand therapy in advanced prostate cancer
Ahmed, B. S., & Ravi, P. K. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251409047 · Cited by 4 · see citing works
Obstacles and improvement strategies for CAR-T cell therapy in solid tumors
Luo, Z., Hu, Q., Ren, M., Wang, L., Zou, Q., Wen, X., Chen, S., Liu, Q., Luo, D., & Guo, Z. (2026) · Discover Oncology · doi:10.1007/s12672-026-04473-8 · Cited by 4 · see citing works
Clinical trials in cancer theranostics with potential near-term impact on clinical practice
Jadvar, H., Doroudinia, A., Conti, P. S., & Colletti, P. M. (2025) · British Journal of Radiology · doi:10.1093/bjr/tqaf017 · Cited by 4 · see citing works
Fang, W., Chen, Y., Nie, M., Zhou, X., Liu, Y., Tao, H., Yang, B., & Wang, X. (2025) · Marine Drugs · doi:10.3390/md23050214 · Cited by 4 · see citing works
Kuo, P. H., Calais, J., & Crosby, M. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01151-7 · Cited by 4 · see citing works
Self-citationMirzaei, S., Schweighofer-Zwink, G., Ofner, H., Bektić, J., Fajković, H., von Guggenberg, E., Ponholzer, A., Kramer, G., Lusuardi, L., Gabriel, M., et al. (2025) · Wiener klinische Wochenschrift · doi:10.1007/s00508-025-02544-4 · Cited by 4 · see citing works
Liukaityte, R., Stenberg, V. Y., Kleinauskas, A., Juzenas, P., Urbanucci, A., & Juzeniene, A. (2025) · Medical Oncology · doi:10.1007/s12032-025-02925-9 · Cited by 4 · see citing works
Theranostics 2.0: Target-driven, artificial intelligence-enabled cancer therapy across tumor types
Oldan, J. D., Anugu, A., Islam, M. Z., Amindarolzarbi, A., Werner, R. A., Pomper, M. G., Sólnes, L. B., Almaguel, F. A., Moschos, S. J., Viglianti, B. L., et al. (2025) · Diagnostic and Interventional Imaging · doi:10.1016/j.diii.2025.07.003 · Cited by 4 · see citing works
Prostate Cancer Treatments and Their Effects on Male Fertility: Mechanisms and Mitigation Strategies
Kaltsas, A., Razos, N., Kratiras, Z., Deligiannis, D., Stavropoulos, M., Adamos, K., Zachariou, A., Dimitriadis, F., Sofikitis, N., & Chrisofos, M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15080360 · Cited by 4 · see citing works
Prostate Cancer Immunotherapy: Time to Move Beyond Checkpoint Inhibitors
Abel, M. L., Warner, A., Karzai, F. H., & Madan, R. A. (2025) · ImmunoTargets and Therapy · doi:10.2147/itt.s549873 · Cited by 4 · see citing works
Suzuki, K., Miyake, H., Inaki, A., Takano, S., Kuboki, Y., Mizowaki, T., Nakamura, K., Ueno, M., Matsumoto, S., Obinata, D., et al. (2025) · International Journal of Clinical Oncology · doi:10.1007/s10147-025-02858-3 · Cited by 4 · see citing works
Therapy strategies to defeat prostate cancer heterogeneity
Jadvar, H., & Iravani, A. (2025) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2025.11.025 · Cited by 4 · see citing works
Emmett, L., Swiha, M. M., Papa, N. P., Subramaniam, S., Crumbaker, M., Joshua, A. M., Nguyen, A., Weickhardt, A. J., Lee, S.-T., Ng, S., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01140-3 · Cited by 4 · see citing works
177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
Mateo, J., & Zurita, A. J. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01919-6 · Cited by 4 · see citing works
Wong, C. H. M., Nicoletti, R., Mazzone, E., & Eapen, R. S. (2024) · Current Opinion in Urology · doi:10.1097/mou.0000000000001234 · Cited by 4 · see citing works
Marshall, C. H., Antonarakis, E. S., & Patnaik, M. M. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101269 · Cited by 4 · see citing works
Stangl‐Kremser, J., Ricaurte‐Fajardo, A., Castellanos, S. H., Martinez‐Fundichely, A., Sun, M., Osborne, J. R., Nauseef, J. T., Tagawa, S. T., & Bander, N. H. (2025) · The Prostate · doi:10.1002/pros.24853 · Cited by 4 · see citing works
Czernin, J. G., Bodei, L., Modlin, I. M., & Calais, J. (2025) · Journal of Nuclear Medicine · doi:10.2967/jnumed.124.269401 · Cited by 4 · see citing works
Oral Toxicities of PSMA-Targeted Therapies: Mitigation Strategies and Translational Opportunities
Emperumal, C. P., Kannan, N., Childs, D. S., & Keenan, B. P. (2025) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2025.102452 · Cited by 3 · see citing works
Mehr, S., & Hauke, R. J. (2025) · Oncology and Therapy · doi:10.1007/s40487-025-00377-9 · Cited by 5 · see citing works
Prostate Cancer Imaging Beyond PSMA: Applications of GRPR, AR, and Amino Acid Tracers
Ali, F. (2025) · Diagnostics · doi:10.3390/diagnostics15212737 · Cited by 3 · see citing works
Vogl, U. M., Merler, S., Angrisani, A., Turco, F., Davis, I. D., Efstathiou, J. A., Fizazi, K. S., James, N. D., Shore, N. D., Small, E. J., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.116131 · Cited by 3 · see citing works
Self-citationMarini, I., Giunta, E. F., Nicolini, S., Grassi, I., Foca, F., Sarnelli, A., Iorio, V. D., Vizza, L., Giani, E., Celli, M., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07661-w · Cited by 3 · see citing works
Bölek, H., Araz, M., Soydal, Ç., Yekedüz, E., Küçük, Ö., & Ürün, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.105088 · Cited by 3 · see citing works
Liu, Y., Wang, X., Pan, X., Huang, X., He, S., Zhang, J., Xu, X., & Song, S. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07704-2 · Cited by 3 · see citing works
Zhu, Y., Zhong, G., Zhang, W., Wei, W., Yin, B., & Zhang, K. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02700-x · Cited by 3 · see citing works
Amsberg, G. V., Bulkley, A., DeCongelio, M., Skiles, G., Grisolano, J., Yang, L., Masurkar, N., Morasso, C., Costanza-McDonald, S., Yin, X., et al. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102519 · Cited by 3 · see citing works
- Authors
- Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., Mahammedi, H., Roubaud, G., Študentová, H., Nagarajah, J., Mellado, B., Montesa-Pino, Á., Kpamegan, E., Ghebremariam, S., Kreisl, T. N., Wilke, C., Lehnhoff, K., Sartor, O., & Fizazi, K.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Research Institute Hospital 12 de Octubre (ES)
- National Center for Tumor Diseases (DE)
- Carolina Urologic Research Center (US)
- BC Cancer Agency (CA)
- Institut Català d'Oncologia (ES)
- Centre Léon Bérard (FR)
- Dana-Farber Cancer Institute (US)
- Centre Jean Perrin (FR)
- Institut Bergonié (FR)
- University Hospital Olomouc (CZ)
- Radboud University Medical Center (NL)
- Hospital Clínic de Barcelona (ES)
- Novartis (Switzerland) (CH)
- Mayo Clinic (US)
- Université Paris-Saclay (FR)
- Corresponding author
- Morris, Michael J
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2024-09
- Volume
- 404
- Issue
- 10459
- Pages
- 1227-1239
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC12121614
- OpenAlex
- W4402552580
- Cited by
- 362
- References
- 47
- Citations by year
- 2026: 204 · 2025: 150 · 2024: 8
- FWCI
- 104.54
- Type
- journal article
- Language
- en
- Update notices
- erratum (2024-12-21)
- Open access
- green
- pmc.ncbi.nlm.nih.gov
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- Novartis Pharmaceuticals Corporation
- Novartis
- National Institutes of Health
- National Cancer Institute (P30 CA008748)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- 177Lu-PSMA-617, androgen receptor pathway inhibitors, abiraterone, enzalutamide, radiographic progression-free survival, radiographic progression, overall survival, radioligand therapy
- MeSH terms
- Progression-Free Survival, Aged, Androstenes, Benzamides, Dipeptides, Heterocyclic Compounds, 1-Ring, Humans, Lutetium, Male, Middle Aged, Nitriles, Phenylthiohydantoin, Radioisotopes, Prostate-Specific Antigen, Taxoids, Androgen Receptor Antagonists, Prostatic Neoplasms, Castration-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
